Word: fda
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...about 30 states in which makers of brand-name drugs, often led by DuPont, have pushed to limit patient access to some generic versions. At times the generic companies have pushed back and won. In 1998 Minnesota gave its consumers access to all the cheaper substitutes approved by the FDA...
...warfarin. "We are only concerned about patient safety," says DuPont spokesman Thomas Barry. Some physicians support DuPont's position because they say warfarin is a tricky drug and doses must be carefully calibrated. The implication is that the brand names do a better job of that. But the FDA says the generic version is safe and has admonished DuPont more than once for stoking false fears in its promotion of Coumadin...
...they're playing a game of 50-state Whack-a-Mole, never knowing where another amendment or rule pushed by their rivals is going to pop up. Take Illinois: last year Barr and its allies persuaded legislators to dissolve a state panel that had delayed marketing of some FDA-approved generics, but Governor George Ryan vetoed the bill. Still, all sides worked out a compromise to give immediate approval to most generics. Barr's lobbyists relaxed. Too soon, it turns out. A month ago, an amendment was quietly tacked onto a new bill to help the poor pay for prescriptions...
EROS ENVY Tired of men having all the fun? The FDA has approved something that may be a remedy. Not for the squeamish, the Eros Clitoral Therapy Device consists of a soft plastic cup (placed over you know where) and a palm-size battery-operated pump. By drawing blood to the clitoris, the device causes engorgement, a key to sexual arousal. In trials 80% of women with female sexual-arousal disorder reported experiencing sexual satisfaction, and 55% said they could reach orgasm more easily. The price of pleasure: $350--and a doctor...
Sources: Good News: Journal of the American Medical Association (5/2/00), FDA; Bad News: Annals of Internal Medicine (5/2/00), Genentech